BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33830457)

  • 1. Prospective analysis of disability and quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
    Bozovic I; Peric M; Arsic Azanjac A; Palibrk A; Bulatovic I; Aleksic D; Peric S; Basta I
    Qual Life Res; 2021 Sep; 30(9):2573-2579. PubMed ID: 33830457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the Serbian version of inflammatory Rasch-built overall disability scale in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
    Peric S; Bozovic I; Pruppers MHJ; Bjelica B; Stevic Z; Faber CG; Merkies ISJ; Basta I
    J Peripher Nerv Syst; 2019 Sep; 24(3):260-267. PubMed ID: 31397933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
    Bozovic I; Kacar A; Peric S; Nikolic A; Bjelica B; Cobeljic M; Petrovic M; Stojanov A; Djuric V; Stojanovic M; Djordjevic G; Martic V; Dominovic A; Vukojevic Z; Basta I
    J Neurol; 2017 Dec; 264(12):2481-2486. PubMed ID: 29086018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic Acquired Polyneuropathy Patient Reported Index (CAPPRI) in chronic inflammatory demyelinating polyradiculoneuropathy.
    Bjelica B; Peric S; Gwathmey K; Sadjadi R; Bozovic I; Burns TM; Basta I
    J Peripher Nerv Syst; 2019 Sep; 24(3):247-252. PubMed ID: 31209940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromuscular disease-specific questionnaire to assess quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
    Kacar A; Bjelica B; Bozovic I; Peric S; Nikolic A; Cobeljic M; Petrovic M; Stojanov A; Djordjevic G; Vukojevic Z; Dominovic-Kovacevic A; Stojanovic M; Stevic Z; Rakocevic-Stojanovic V; Lavrnic D; Basta I
    J Peripher Nerv Syst; 2018 Mar; 23(1):11-16. PubMed ID: 29360221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year follow-up study of neuropathic pain in chronic inflammatory demyelinating polyradiculoneuropathy.
    Bjelica B; Peric S; Bozovic I; Kacar A; Cobeljic M; Dejanovic I; Stevic Z; Basta I
    J Peripher Nerv Syst; 2019 Jun; 24(2):180-186. PubMed ID: 30973184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axonal damage determines clinical disability in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A prospective cohort study of different CIDP subtypes and disease stages.
    Grüter T; Motte J; Bulut Y; Kordes A; Athanasopoulos D; Fels M; Schneider-Gold C; Gold R; Fisse AL; Pitarokoili K
    Eur J Neurol; 2022 Feb; 29(2):583-592. PubMed ID: 34687104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of environmental factors and physical activity on disability and quality of life in CIDP.
    Doneddu PE; Bianchi E; Cocito D; Manganelli F; Fazio R; Filosto M; Beghi E; Mazzeo A; Cosentino G; Cortese A; Jann S; Clerici AM; Antonini G; Siciliano G; Marfia GA; Briani C; Lauria G; Rosso T; Cavaletti G; Carpo M; Benedetti L; Schenone A; Liberatore G; Peci E; Spina E; Tronci S; Cotti Piccinelli S; Toscano A; Gentile L; Piccolo L; Leonardi L; Mataluni G; Ruiz M; Sabatelli M; Santoro L; Nobile-Orazio E;
    J Neurol; 2020 Sep; 267(9):2683-2691. PubMed ID: 32430573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy.
    Klehmet J; Tackenberg B; Haas J; Kieseier BC
    BMC Neurol; 2023 May; 23(1):207. PubMed ID: 37237267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study.
    Merkies IS; Hughes RA; Donofrio P; Bril V; Dalakas MC; Hanna K; Hartung HP; Latov N; van Doorn PA; Deng C;
    J Peripher Nerv Syst; 2010 Sep; 15(3):208-15. PubMed ID: 21040143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of tremor on disability assessment in chronic inflammatory demyelinating polyradiculoneuropathy.
    van Veen R; Pallada G; Wieske L; Ten Holter SEM; van Rootselaar AF; Verhamme C; de Bie RMA; van Schaik IN; Merkies ISJ; Dijk JM; Eftimov F
    J Peripher Nerv Syst; 2023 Mar; 28(1):58-68. PubMed ID: 36571466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychometric longitudinal evaluation of the Chronic Acquired Polyneuropathy Patient-Reported Index (CAPPRI) in patients with chronic inflammatory demyelinating polyneuropathy.
    Sadjadi R; Peric S; Gwathmey K; Bozovic I; Aleksa P; Bjelica B; Burns T; Basta I
    Muscle Nerve; 2021 Jan; 63(1):84-88. PubMed ID: 33043466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective analysis of gait characteristics in chronic inflammatory demyelinating polyradiculoneuropathy.
    Bozovic I; Peric S; Basta I; Rakocevic-Stojanovic V; Lavrnic D; Stevic Z; Radovanovic S
    J Clin Neurosci; 2020 Oct; 80():6-10. PubMed ID: 33099368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.
    Hughes RA; Donofrio P; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Latov N; Merkies IS; van Doorn PA;
    Lancet Neurol; 2008 Feb; 7(2):136-44. PubMed ID: 18178525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.
    Hughes R; Dalakas MC; Merkies I; Latov N; Léger JM; Nobile-Orazio E; Sobue G; Genge A; Cornblath D; Merschhemke M; Ervin CM; Agoropoulou C; Hartung HP;
    Lancet Neurol; 2018 Aug; 17(8):689-698. PubMed ID: 30001923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Employment status of patients with chronic inflammatory demyelinating polyradiculoneuropathy.
    Bjelica B; Basta I; Bozovic I; Kacar A; Nikolic A; Dominovic-Kovacevic A; Vukojevic Z; Martic V; Stojanov A; Djordjevic G; Petrovic M; Stojanovic M; Peric S
    J Peripher Nerv Syst; 2018 Sep; 23(3):178-182. PubMed ID: 29999199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Getting closer to patients: the INCAT Overall Disability Sum Score relates better to patients' own clinical judgement in immune-mediated polyneuropathies.
    Merkies IS; Schmitz PI
    J Neurol Neurosurg Psychiatry; 2006 Aug; 77(8):970-2. PubMed ID: 16549419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impairment and disability in 20 CIDP patients according to disease activity status.
    Panaite PA; Renaud S; Kraftsik R; Steck AJ; Kuntzer T
    J Peripher Nerv Syst; 2013 Sep; 18(3):241-6. PubMed ID: 24028192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nerve Ultrasound Predicts Treatment Response in Chronic Inflammatory Demyelinating Polyradiculoneuropathy-a Prospective Follow-Up.
    Härtig F; Ross M; Dammeier NM; Fedtke N; Heiling B; Axer H; Décard BF; Auffenberg E; Koch M; Rattay TW; Krumbholz M; Bornemann A; Lerche H; Winter N; Grimm A
    Neurotherapeutics; 2018 Apr; 15(2):439-451. PubMed ID: 29435815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance.
    Merkies IS; van Nes SI; Hanna K; Hughes RA; Deng C
    J Neurol Neurosurg Psychiatry; 2010 Nov; 81(11):1194-9. PubMed ID: 20647554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.